KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open-label, phase II/III study.

Takaomi Hagi, Yukinori Kurokawa, Takeshi Omori, Yusuke Akamaru, Keijiro Sugimura, Masaaki Motoori, Jin Matsuyama, Takuro Saito, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Toshio Shimokawa, Hidetoshi Eguchi, Yuichiro Doki

Gastric Cancer 28(5) 993-1003

PMID40638018
PMCIDPMC12378285
DOI10.1007/s10120-025-01635-5
发表日期2025-07-10
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Excessive surgical stress induces inflammatory cytokine release, negatively impacting prognosis in patients with malignancies. This study aimed to determine whether the anti-inflammatory effect of a corticosteroid (CS) would improve prognosis when administered intraoperatively to patients with resectable gastric cancer. METHODS: In this multicenter, randomized, open-label, phase II/III study, patients with cStage II-III gastric cancer were randomized to CS administration or non-administration (control) groups. Patients in the CS group received 5 mg/kg of methylprednisolone just before the skin incision during surgery. The primary endpoints were the highest postoperative serum level of C-reactive protein (CRPmax) in the phase II portion, and recurrence-free survival (RFS) in the phase III portion. RESULTS: Between December 2016 and February 2019, 410 patients were enrolled. In the phase II portion, CRPmax was significantly lower in the CS group than in the control group (mean, 10.7 vs 14.3 mg/dL, respectively; P = 0.009). In the phase III portion, 3-year RFS rates in the CS (n = 202) and control (n = 204) groups were 67.2% and 63.0%, respectively, indicating no significant difference (hazard ratio, 0.807 [95% confidence interval, 0.590-1.105]; log-rank P = 0.182). Subgroup analysis showed that both histological type and clinical stage had significant interactions with RFS, suggesting a potential survival benefit of CS administration in patients with differentiated histological-type or cStage III gastric cancer. CONCLUSIONS: Intraoperative CS administration mitigated postoperative CRP elevation but did not result in significantly improved survival in patients with cStage II-III gastric cancer. The study is registered with UMIN-CTR, number UMIN000024465.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 3

Fig. 3 Kaplan–Meier survival curves of a recurrence-free survival and b overall survival in all randomly assigned patients

A

recurrence-free survival

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

overall survival

Fig. 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial profile
非 KM Figure
Fig. 2Fig. 2 Postoperative serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6). Serum levels of CRP on postoperative a day 1 and b day 3, and c the highest postoperative level (CRP max ). d Serum levels of IL-6 on postoperative day 1. Data are means ± standard error
非 KM Figure
Fig. 4Fig. 4 Subgroup analyses of recurrence-free survival (RFS). The forest plot presents hazard ratios (HRs) with 95% confidence intervals (CIs, blue bars) for RFS events in patients assigned to the corticosteroid (CS) group (red squares). *Four patients with neuroendocrine carcinoma and three patients whose histological type was unavailable were excluded. † Twelve patients who did not undergo gastrectomy were excluded
非 KM Figure